Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A piece by HealthITAnalytics cited a study pubished in the December 2022 issue of The American Journal of Managed Care® (AJMC®). The study, “On the Impact of Predictive Analytics–Driven Disease Management Interventions,” showed that predictive analytics–driven disease management outperforms standard of care among patients with chronic heart failure.
An article by Wired referenced a study published in a 2016 supplement to AJMC®, titled “Economic Costs of Hemophilia and the Impact of Prophylactic Treatment on Patient Management.” The study indicated that intravenous infusions for the management of hemophilia cost patients an average of $127,194 per year.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More